By mitigating pro-inflammatory signaling, particularly through NF-κB inhibition, the AKBA + Cis regimen may improve the therapeutic index of chemotherapy and reshape the tumor microenvironment to favor apoptosis over survival [19,20]. Here, NFKB1 is linked to neoplasm.